The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BSH/ISH 2016 | The consequences of epigenetic drugs in the treatment of AML
Charles Craddock, CBE, FRCP, FRCPath, DPhil, from Queen Elizabeth Hospital, Birmingham, UK explains how epigenetic drugs may have a capacity to modulate the immune system post-transplant in acute myeloid leukemia (AML). By demethylating the FOXP3 promoter it may be able to accelerate Treg reconstitution post-allograft and thereby potentially suppressing graft versus host disease. Prof Craddock also discusses the clinical trial RICAZA (ISRCTN36825171) in which 40 patients post-transplant azacidine was well-tolerated. Recorded at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH), held in Glasgow, Scotland
